Your session is about to expire
← Back to Search
ROCC Trial Summary
This trial is comparing two methods of treatment for cervical cancer to see which one is more effective.
- Cervical Cancer
ROCC Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
ROCC Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
ROCC Trial Design
Find a Location
Who is running the clinical trial?
- Your cancer type should be one of the specific types listed, and not include certain types like neuroendocrine or specific types of adenocarcinoma.
- Group 1: Robotic radical hysterectomy
- Group 2: Open radical hysterectomy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the geographic scope of this trial's implementation?
"This medical trial is being held at St. Vincent Hospital and Health Care Center Inc in Indianapolis, Indiana, Chattanooga's Program in Women's Oncology in Chattanooga, Tennessees Oncolois, Indiana, Chattanooga's Program in Women's Oncology in Chattanooga, Tennessee, Kettering Health Cancer Center in Kettering Ohio as well as 7 other sites."
Is there an enrollment period for participants currently open?
"According to clinicaltrials.gov, this experiment is actively enrolling participants. The trial was first publicized on March 22nd 2022 and the most recent amendment made to it occurred April 13th of that year."
How many participants are engaged in this experiment?
"Affirmative. Details on clinicaltrials.gov demonstrate that, as of April 13th 2022, this research is still recruiting volunteers. Initially posted on March 22nd 2022, the trial seeks 840 participants from 7 distinct medical facilities."
Share this study with friends